PB0917 - The Ottawa Score did not predict recurrent venous thromboembolism in the prospective TROPIQUE cohort study

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Corinne Frere, MD, PhD

MD,PhD
AP.HP Sorbonne Université
Paris, Ile-de-France, France

Co-Author(s)

PD

Philippe Debourdeau

Oncologist
Institut Sainte-Catherine
Avignon, Provence-Alpes-Cote d'Azur, France
Al

Anne lamblin

Medical Scientist Liaison
LEO Pharma
Voisins-le-Bretonneux, Ile-de-France, France
FC

Francis Cajfinger

Oncologist
Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
NF

Nicolas Falvo

Oncologist
CHU de Dijon-Bourgogne
Dijon, Bourgogne, France
yb

ygal benhamou

MD,PhD
university hospital of rouen
rouen, Haute-Normandie, France
mS

marie-antoinette Sevestre

Staff Physician
Amiens University Hospital
Amiens, Picardie, France
DF

Dominique Farge

Professor
Université de Paris
Paris, Ile-de-France, France

Background: Recurrent venous thromboembolism (VTE) occurs frequently in cancer patients despite curative anticoagulation. The Ottawa score was designed to stratify patients according to their risk of recurrent VTE within 6 months after starting anticoagulation.

Aims: To analyze the predictive value of the Ottawa risk score among cancer patients from the TROPIQUE study cohort.

Methods: TROPIQUE was a prospective multicenter observational cohort of adult cancer patients with newly diagnosed VTE treated with low molecular weight heparin (LMWH) for 6 months. For all patients included in the study, we retrospectively calculated the modified Ottawa score as follows: female sex, lung cancer, and prior history of VTE, each accounting for 1 point; breast cancer and cancer stage I + II each accounting for -1 point. Patients with an Ottawa score ≥ 1 were classified at high-risk for recurrent VTE. The primary endpoint was recurrent VTE within the first 6 months of anticoagulation. All clinical events were centrally adjudicated. The Fine-Gray competing risk model was used to take into account the competing risk of death.

Results: A total of 409 patients were analyzed on an intention-to-treat basis. At study entry, patients were aged 65.0±12.1 years. The majority of index VTE events were deep vein thrombosis (47.2%) or pulmonary embolism (35.5%). The main primary cancer site was gastrointestinal (24.4%), followed by lung (17.4%) and breast (15.9%), and 249 (60.9%) patients had metastatic disease. The modified Ottawa score was high (≥1) in 163 (39.9%) patients. The overall 6-month cumulative incidence of recurrent VTE was 6.2 % (95% CI: 4.0-9.5), and 6.6% (95% CI: 4.0-10.7) versus 5.7% (95%CI: 2.6-12.5) in the Ottawa low-intermediate and high-risk groups, respectively. The C-statistic value was 0.52 (95% CI: 0.46-0.58).

Conclusion(s): In this prospective cohort of cancer patients receiving LMWH for VTE, the Ottawa score failed to accurately predict the risk of recurrent VTE.